Cytochrome P450 1B1 (CYP1B1) polymorphisms are associated with clinical outcome of docetaxel in non-small cell lung cancer (NSCLC) patients

Vasile, Enrico; Tibaldi, Carmelo; León, Guillermo; D’Incecco, Armida; Giovannetti, Elisa

doi:10.1007/s00432-014-1880-3

Cited by 20 publications

(21 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These investigators, however, observed no association between CYP1B1*4 polymorphisms and survival in patients with NSCLC. In line with Vasile et al 19 , Ada et al 7 previously showed that the CYP1B1*4 polymorphism was not associated with survival in patients with NSCLC, although a notable trend towards worsening of survival in CYP1B1*4 mutant allele carriers was determined (Table 4).…”

Section: The Associations Between Cyp Polymorphisms and Response To Csupporting

confidence: 57%

“…7 There are only two studies in regard to the influences of CYP1B1 polymorphisms on survival in lung cancer (Table 4). Recently, Vasile et al 19 demonstrated that CYP1B1*3 mutant allele carriers had shorter survival compared with wild-type allele carriers. These investigators, however, observed no association between CYP1B1*4 polymorphisms and survival in patients with NSCLC.…”

Section: The Associations Between Cyp Polymorphisms and Response To Cmentioning

confidence: 99%

“…7,18,19 Li et al 18 found that wild-type allele carriers of the CYP1A1 gene had a better response to non-platinum drug therapy only, but not to platinum-based chemotherapy, than those of variant allele carriers of the gene. There was no influence of the CYP1A1*2C polymorphism on the response to platinumbased chemotherapy in patients with NSCLC.…”

Section: The Associations Between Cyp Polymorphisms and Response To Cmentioning

confidence: 99%

“…17 The therapeutic efficiency and survival period may vary among patients with lung cancer because CYPs metabolize several chemotherapeutic agents depending on CYP activity. 16,18,19 Therefore, the relationship between CYP gene polymorphisms and response to chemotherapy and survival in patients with cancer is currently a major area of research. All these kinds of information obtained from studies are necessary and important to lead physicians toward the new era of precision medicine in lung cancer therapy.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Cytochrome P-450 Polymorphisms and Clinical Outcome in Patients with Non-Small Cell Lung Cancer

İşcan

Ada

2017

tjps

View full text Add to dashboard Cite

ÖZAkciğer kanseri dünyada artan bir sağlık sorunudur. Akciğer kanseri hastalarının çoğu küçük hücreli dışı akciğer kanseridir (KHDAK). Bu hastalar genelde ilk basamakta standart platin bazlı kemoterapi ile tedavi olmaktadır. Bu hastalarda kemoterapiye yanıt ise düşük düzeyde olmakta ve tedaviye yanıtta bireyler arasında büyük farklılıklar görülmektedir. Genetik polimorfizmlerin ilaca karşı alınan yanıt ile sağkalım üzerinde etkili olduğu hipotezini destekleyen kanıtlar giderek artmaktadır. Sitokrom P450 (CYP) enzimleri antineoplastik ilaçları metabolize etmekte ve ilaç direncine neden olabilmektedir. Polimorfik CYP'lerin enzim aktiviteleri değişkenlik göstermekte ve dolayısıyla akciğer kanseri hastalarının kemoterapiye yanıtlarında ve sağkalım süreleri üzerinde etkileri olabilmektedirler. Bu derlemede, özellikle platin bazlı kemoterapi alan KHDAK hastalarının prognozunda klinisyenlere yararlı olabilecek, CYP1A1, CYP1B1, CYP2D6, CYP2E1 ve CYP3A4 gen polimorfizmlerinin bu tedaviyi alan KHDAK hastalarının kemoterapiye yanıt ve sağkalım süreleri üzerindeki etkileri ile ilgili olarak son yıllarda elde edilen bulgular ortaya konmaktadır. Anahtar kelimeler: CYP, polimorfizm, kemoterapiye yanıt, sağkalım, akciğer kanseri Lung cancer is an increasing worldwide public health problem. Most patients with lung cancer have non-small cell lung cancer (NSCLC). These patients are mainly treated with standard platinum-based chemotherapy. Poor response and great inter-individual variety in treatment response occurs among these patients. There is accumulating evidence to support the hypothesis that genetic polymorphisms alter the drug response and survival. Cytochrome P450 (CYP) enzymes metabolize antineoplastic drugs and are involved in drug resistance. Polymorphic CYPs have altered enzyme activities and thus they may influence the response to chemotherapy and survival in patients with lung cancer. In the current review, recent findings with respect to the role of mainly CYP1A1, CYP1B1, CYP2D6, CYP2E1 and CYP3A4 gene polymorphisms in response to chemotherapy and survival in patients with NSCLC have been provided, which could be useful for clinicians in the prognosis of these patients who are mainly treated with platinum-based chemotherapy.

show abstract

Section: The Associations Between Cyp Polymorphisms and Response To Csupporting

confidence: 57%

Section: The Associations Between Cyp Polymorphisms and Response To Cmentioning

confidence: 99%

Section: The Associations Between Cyp Polymorphisms and Response To Cmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Cytochrome P-450 Polymorphisms and Clinical Outcome in Patients with Non-Small Cell Lung Cancer

İşcan

Ada

2017

tjps

View full text Add to dashboard Cite

show abstract

“…The 5-year survival rate of NSCLC is estimated to be 15% and the median survival time is less than 10 months (NCCN, 2011). An increasing number of genomic studies have reported potential therapeutic targets in lung cancer, such as XRCC1, XPF, XPG, CYP1B1, and OPN genes (Hao et al, 2014;Shi et al, 2015;Vasile et al, 2015;Zou and Zhao, 2015).…”

Section: Introductionmentioning

confidence: 99%

Role of GSTM1, GSTT1, and GSTP1 IIe105Val gene polymorphisms in the response to chemotherapy and overall survival of advanced non-small cell lung cancer

Jia¹,

Sun

Jia

et al. 2016

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. We evaluated the association between GSTM1, GSTT1, and GSTP1 IIe105Val gene polymorphisms and treatment outcomes of advanced non-small cell lung carcinoma. Between January 2010 and December 2012, a total of 244 patients with non-small cell lung carcinoma were recruited from Yiwu Central Hospital. The GSTM1, GSTT1, and GSTP1 IIe105Val gene polymorphisms were analyzed by polymerase chain reaction-restriction fragment length polymorphism and the results were statistically analyzed. Conditional regression analysis, showed that individuals carrying the null GSTM1 were associated with an increased risk of response to chemotherapy when 2 W. Jia et al. Genetics and Molecular Research 15 (3): gmr.15037668 compared to the present GSTM1 (odds ratio = 1.88, 95% confidence interval (CI) = 1.01-3.47). Moreover, the GG genotype of GSTP1 IIe105Val was associated with a better response to chemotherapy compared to the AA genotype (odds ratio = 2.77, 95%CI = 1.14-6.64). The null GSTM1 genotype was associated with a lower risk of death from all causes when compared with the present GSTM1 genotype (hazard ratio = 2.16, 95%CI = 1.10-4.38). Moreover, the GG genotype of GSTP1 IIe105Val was correlated with a reduced risk of death from all causes compared with the AA genotype (hazard ratio = 2.94, 95%CI = 1.11-8.68). In conclusion, we found that the null GSTM1 and the GG genotype of GSTP1 IIe105Val were correlated with a good response to chemotherapy and improved overall survival of advanced non-small cell lung carcinoma patients.

show abstract

Retrospective analysis of second-line chemotherapy outcomes with paclitaxel or docetaxel in correlation with STMN1 polymorphism in advanced non-small cell lung cancer patients

et al. 2015

View full text Add to dashboard Cite

show abstract

Cytochrome P450 1B1 (CYP1B1) polymorphisms are associated with clinical outcome of docetaxel in non-small cell lung cancer (NSCLC) patients

Abstract: CYP1B1 4326C>G polymorphism emerged as possible prognostic/predictive marker of activity and efficacy of docetaxel in NSCLC patients.

Cited by 20 publications

References 23 publications

Cytochrome P-450 Polymorphisms and Clinical Outcome in Patients with Non-Small Cell Lung Cancer

Cytochrome P-450 Polymorphisms and Clinical Outcome in Patients with Non-Small Cell Lung Cancer

Role of GSTM1, GSTT1, and GSTP1 IIe105Val gene polymorphisms in the response to chemotherapy and overall survival of advanced non-small cell lung cancer

Retrospective analysis of second-line chemotherapy outcomes with paclitaxel or docetaxel in correlation with STMN1 polymorphism in advanced non-small cell lung cancer patients

Contact Info

Product

Resources

About